Ernexa Therapeutics Inc.
ERNA
$0.29
$0.001.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -99.83% | 201.23% | 365.22% | 755.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -99.83% | 201.23% | 365.22% | 755.88% |
| Cost of Revenue | -- | -100.00% | -117.54% | -85.83% | -59.32% |
| Gross Profit | -- | -99.77% | 404.44% | 478.79% | 389.29% |
| SG&A Expenses | -60.69% | -67.25% | -54.13% | -33.93% | -11.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.75% | -52.56% | -44.69% | -30.73% | -14.03% |
| Operating Income | 45.98% | 51.17% | 46.50% | 32.88% | 16.57% |
| Income Before Tax | 68.26% | 59.23% | -82.53% | -101.11% | -105.39% |
| Income Tax Expenses | -250.00% | 86.67% | 780.00% | 950.00% | 1,100.00% |
| Earnings from Continuing Operations | 68.38% | 59.18% | -82.71% | -101.29% | -105.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.38% | 59.18% | -82.71% | -101.29% | -105.55% |
| EBIT | 45.98% | 51.17% | 46.50% | 32.88% | 16.57% |
| EBITDA | 45.92% | 51.18% | 46.61% | 33.12% | 16.90% |
| EPS Basic | 97.04% | 95.73% | -18.87% | -46.75% | -79.30% |
| Normalized Basic EPS | 93.63% | 91.33% | 67.78% | 42.15% | 12.66% |
| EPS Diluted | 97.04% | 95.73% | -18.87% | -46.75% | -79.30% |
| Normalized Diluted EPS | 93.63% | 91.33% | 67.78% | 42.15% | 12.66% |
| Average Basic Shares Outstanding | 592.90% | 1,252.13% | 707.48% | 376.14% | 156.88% |
| Average Diluted Shares Outstanding | 592.90% | 1,252.13% | 707.48% | 376.14% | 156.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 1.00% | 0.75% | 0.76% |